company background image
ANGN

Angion Biomedica NasdaqGS:ANGN Stock Report

Last Price

US$1.12

Market Cap

US$33.6m

7D

-41.4%

1Y

-90.3%

Updated

04 Jul, 2022

Data

Company Financials +
ANGN fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

ANGN Stock Overview

Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases.

Angion Biomedica Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Angion Biomedica
Historical stock prices
Current Share PriceUS$1.12
52 Week HighUS$14.18
52 Week LowUS$1.03
Beta0
1 Month Change-28.66%
3 Month Change-49.09%
1 Year Change-90.29%
3 Year Changen/a
5 Year Changen/a
Change since IPO-93.42%

Recent News & Updates

Jun 29

Angion to discontinue phase 2 trial of ANG-3070 in patients with kidney disease

Angion Biomedica (NASDAQ:ANGN) on Wednesday said it would discontinue its phase 2 JUNIPER trial evaluating its inhibitor ANG-3070 for the treatment of kidney diseases. The trial is being discontinued based upon a reassessment of the risk/benefit profile of ANG-3070 in patients with established serious kidney disease. The reassessment was done after an unexpected and substantial decline in kidney function in a patient in the trial’s drug treatment arm. An analysis of the blinded patient data also did not detect any reduction in proteinuria, which is an early indication of kidney disease. "We will continue to evaluate the potential of ANG-3070 as a treatment for patients with idiopathic pulmonary fibrosis, as well as to consider all strategic and operational options for Angion and its pipeline going forward,” said ANGN CEO Jay Venkatesan. ANGN also said it expects to report cash and cash equivalents in excess of $60M at the end of Q2. ANGN stock earlier closed -6% at $1.71.

Shareholder Returns

ANGNUS PharmaceuticalsUS Market
7D-41.4%-0.7%-2.2%
1Y-90.3%10.4%-21.2%

Return vs Industry: ANGN underperformed the US Pharmaceuticals industry which returned 10.4% over the past year.

Return vs Market: ANGN underperformed the US Market which returned -21.2% over the past year.

Price Volatility

Is ANGN's price volatile compared to industry and market?
ANGN volatility
ANGN Average Weekly Movement21.0%
Pharmaceuticals Industry Average Movement11.9%
Market Average Movement8.1%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.3%

Stable Share Price: ANGN is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 21% a week.

Volatility Over Time: ANGN's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
199871Jay Venkatesanhttps://www.angion.com

Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company’s lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung. It also develops ANG-3777, a hepatocyte growth factor mimetic to treat acute organ injuries, such as delayed graft function; ROCK2 inhibitors programs for fibrotic diseases; and CYP11B2 inhibitor program.

Angion Biomedica Fundamentals Summary

How do Angion Biomedica's earnings and revenue compare to its market cap?
ANGN fundamental statistics
Market CapUS$33.55m
Earnings (TTM)-US$32.13m
Revenue (TTM)US$29.59m

1.1x

P/S Ratio

-1.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ANGN income statement (TTM)
RevenueUS$29.59m
Cost of RevenueUS$43.30m
Gross Profit-US$13.71m
Other ExpensesUS$18.42m
Earnings-US$32.13m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.07
Gross Margin-46.34%
Net Profit Margin-108.57%
Debt/Equity Ratio0.4%

How did ANGN perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is ANGN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ANGN?

Other financial metrics that can be useful for relative valuation.

ANGN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Sales Ratio vs Peers

How does ANGN's PS Ratio compare to its peers?

ANGN PS Ratio vs Peers
The above table shows the PS ratio for ANGN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average10.1x
EVFM Evofem Biosciences
3x46.7%US$34.0m
BFRI Biofrontera
1.2x41.2%US$34.1m
ACUR Acura Pharmaceuticals
14.5xn/aUS$32.6m
NTRB Nutriband
21.8x68.3%US$32.0m
ANGN Angion Biomedica
1.1x5.4%US$33.6m

Price-To-Sales vs Peers: ANGN is good value based on its Price-To-Sales Ratio (1.1x) compared to the peer average (10.1x).


Price to Earnings Ratio vs Industry

How does ANGN's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

Price-To-Sales vs Industry: ANGN is good value based on its Price-To-Sales Ratio (1.1x) compared to the US Pharmaceuticals industry average (4.1x)


Price to Sales Ratio vs Fair Ratio

What is ANGN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ANGN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.1x
Fair PS Ratio1.4x

Price-To-Sales vs Fair Ratio: ANGN is good value based on its Price-To-Sales Ratio (1.1x) compared to the estimated Fair Price-To-Sales Ratio (1.4x).


Share Price vs Fair Value

What is the Fair Price of ANGN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ANGN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ANGN's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ANGN's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Angion Biomedica forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


5.4%

Forecasted annual revenue growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if ANGN's forecast earnings growth is above the savings rate (1.9%).

Earnings vs Market: Insufficient data to determine if ANGN's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if ANGN's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: ANGN's revenue (5.4% per year) is forecast to grow slower than the US market (8.2% per year).

High Growth Revenue: ANGN's revenue (5.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ANGN's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Angion Biomedica performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-18.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ANGN is currently unprofitable.

Growing Profit Margin: ANGN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ANGN is unprofitable, and losses have increased over the past 5 years at a rate of 18.3% per year.

Accelerating Growth: Unable to compare ANGN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ANGN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.9%).


Return on Equity

High ROE: ANGN has a negative Return on Equity (-47.81%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Angion Biomedica's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ANGN's short term assets ($76.2M) exceed its short term liabilities ($10.4M).

Long Term Liabilities: ANGN's short term assets ($76.2M) exceed its long term liabilities ($3.7M).


Debt to Equity History and Analysis

Debt Level: ANGN has more cash than its total debt.

Reducing Debt: Insufficient data to determine if ANGN's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ANGN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ANGN has less than a year of cash runway if free cash flow continues to reduce at historical rates of 32.8% each year


Discover healthy companies

Dividend

What is Angion Biomedica current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ANGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ANGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ANGN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ANGN's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ANGN has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Jay Venkatesan (50 yo)

4.17yrs

Tenure

US$2,539,199

Compensation

Dr. Jay R. Venkatesan, Ph D., M.D. MBA., serves as Chairman of Angion Biomedica Corp. since January 2022 and also serves as its President since January 2019 and has been its Chief Executive Officer & Direc...


CEO Compensation Analysis

Compensation vs Market: Jay's total compensation ($USD2.54M) is above average for companies of similar size in the US market ($USD799.15K).

Compensation vs Earnings: Jay's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: ANGN's management team is considered experienced (2.8 years average tenure).


Board Members

Experienced Board: ANGN's board of directors are considered experienced (3.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: ANGN insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Angion Biomedica Corp.'s employee growth, exchange listings and data sources


Key Information

  • Name: Angion Biomedica Corp.
  • Ticker: ANGN
  • Exchange: NasdaqGS
  • Founded: 1998
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$33.554m
  • Shares outstanding: 29.96m
  • Website: https://www.angion.com

Number of Employees


Location

  • Angion Biomedica Corp.
  • 51 Charles Lindbergh Boulevard
  • Uniondale
  • New York
  • 11553
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/07/04 00:00
End of Day Share Price2022/07/01 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.